pixnio
Investors who bet on the fall in shares of the American biotech company Moderna lost about $ 1.85 billion this year, Bloomberg reports with reference to the analytical company S3 Partners. In November alone, such investors lost $ 790 million.
Moderna is one of the companies developing a coronavirus vaccine. The firm said on Monday that interim results from a third phase of trials of the vaccine were 94.5% effective. Moderna CEO Stéphane Bancel announced a "turning point" in the development process. The growth in the value of the company’s securities reached 15%, Bloomberg notes.
So far, Moderna has reported the best test results among vaccine developers. Last week, Pfizer and BioNTech reported that a third phase of trials has demonstrated 90 percent effectiveness of their vaccine. The developers of the Russian vaccine against COVID-19 Sputnik V estimated its effectiveness at 92%.
The news about the effectiveness of the vaccine also helped go up companies dependent on the resumption of economic activity, while securities that benefited from the introduction of self-isolation regimes lagged behind them, Bloomberg notes. Thus, the shares of the Zoom videoconferencing service became 3.25% cheaper and cost $ 390.48 per share. Last week, following news of the effectiveness of the vaccine from Pfizer and BioNTech, the Zoom founder's wealth fell by almost 20%.
source: bloomberg.com
Moderna is one of the companies developing a coronavirus vaccine. The firm said on Monday that interim results from a third phase of trials of the vaccine were 94.5% effective. Moderna CEO Stéphane Bancel announced a "turning point" in the development process. The growth in the value of the company’s securities reached 15%, Bloomberg notes.
So far, Moderna has reported the best test results among vaccine developers. Last week, Pfizer and BioNTech reported that a third phase of trials has demonstrated 90 percent effectiveness of their vaccine. The developers of the Russian vaccine against COVID-19 Sputnik V estimated its effectiveness at 92%.
The news about the effectiveness of the vaccine also helped go up companies dependent on the resumption of economic activity, while securities that benefited from the introduction of self-isolation regimes lagged behind them, Bloomberg notes. Thus, the shares of the Zoom videoconferencing service became 3.25% cheaper and cost $ 390.48 per share. Last week, following news of the effectiveness of the vaccine from Pfizer and BioNTech, the Zoom founder's wealth fell by almost 20%.
source: bloomberg.com
